These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31249748)

  • 1. Diethylstilbestrol in the Treatment of Castration-resistant Prostate Cancer: A Lower-middle-income Country Experience.
    Ali A; Khalil MAI; Khan N; Abu Bakar M; Amjad A; Ahmed I; Mir K
    Cureus; 2019 Apr; 11(4):e4470. PubMed ID: 31249748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
    Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
    Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diethylstilbestrol in castration-resistant prostate cancer.
    Wilkins A; Shahidi M; Parker C; Gunapala R; Thomas K; Huddart R; Horwich A; Dearnaley D
    BJU Int; 2012 Dec; 110(11 Pt B):E727-35. PubMed ID: 23110500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol.
    Shamash J; Powles T; Sarker SJ; Protheroe A; Mithal N; Mills R; Beard R; Wilson P; Tranter N; O'Brien N; McFaul S; Oliver T
    Br J Cancer; 2011 Feb; 104(4):620-8. PubMed ID: 21285990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer.
    Siddiqui K; Abbas F; Biyabani SR; Ather MH; Talati J
    J Pak Med Assoc; 2004 Sep; 54(9):445-7. PubMed ID: 15518364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Change of the LHRH analogue in progressive castration-refractory prostate cancer].
    Heidenreich A; Porres D; Epplen R; van Erps T; Pfister D
    Urologe A; 2012 Sep; 51(9):1282-7. PubMed ID: 22733398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diethylstilboestrol (1 mg) in the management of castration-resistant prostate cancer.
    Turo R; Tan K; Thygesen H; Sundaram SK; Chahal R; Prescott S; Cross WR
    Urol Int; 2015; 94(3):307-12. PubMed ID: 25342383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
    Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
    Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
    Aggarwal R; Weinberg V; Small EJ; Oh W; Rushakoff R; Ryan CJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E71-6. PubMed ID: 19815485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.
    Bonde TM; Westerberg M; Aly M; Eklund M; Adolfsson J; Bill-Axelson A; Garmo H; Stattin P; Robinson D
    Scand J Urol; 2022 Jun; 56(3):169-175. PubMed ID: 35548951
    [No Abstract]   [Full Text] [Related]  

  • 14. Current role of diethylstilbestrol in the management of advanced prostate cancer.
    Bosset PO; Albiges L; Seisen T; de la Motte Rouge T; Phé V; Bitker MO; Rouprêt M
    BJU Int; 2012 Dec; 110(11 Pt C):E826-9. PubMed ID: 22578092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
    Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
    Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.
    Clemons J; Glodé LM; Gao D; Flaig TW
    Urol Oncol; 2013 Feb; 31(2):198-204. PubMed ID: 21795073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and toxicity of oral Fosfestrol in metastatic castration-resistant prostate cancer-a real-world experience.
    Nandini Devi R; Praveen Kumar Shenoy VP; Ismail I; Avaronnan M
    Ecancermedicalscience; 2023; 17():1589. PubMed ID: 37799959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.